Biosimilar and Interchangeable Biologics: From Cell Line to Commercial Launch (Hardback)

Sarfaraz K. Niazi

Edité par Apple Academic Press Inc., 2016
ISBN 10: 1482298910 / ISBN 13: 9781482298918
Ancien(s) ou d'occasion / Hardback / Quantité : 0
Disponible auprès d'autres vendeurs
Afficher tous les  exemplaires de ce livre

Au sujet du livre

Ce livre n'est malheureusement plus disponible. AbeBooks dispose cependant de millions de livres. Ci-dessous, nous vous proposons une liste de livres pouvant correspondre à votre recherche.

Description :

Language: English Brand New Book. What s the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch covers the strategic and tactical elements of biosimilars in two volumes. The first volume, Biosimilars and Interchangeable Biologics: Strategic Elements, explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets. This volume also examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. The second volume, Biosimilars and Interchangeable Biologics: Tactical Elements, explores the development and manufacturing of biosimilars and targets challenges surrounding the creation of these products. This includes manufacturing, production costs, and intellectual property barriers, particularly in regulated markets (regulatory agencies are still in the process of developing guidelines). It addresses the complexity of biological drugs, and it discusses specific structural elements vital to the functionality, immunogenicity, and safety of biosimilar products. This volume also provides an overall understanding of the hurdles, difficulties, and practicalities of developing a strong plan. It introduces a step-by-step approach for creating a strategy that helps develop and manufacture a biosimilar product while reducing overall production costs and meeting the requirements of biosimilarity based on analytical and functional, pharmacokinetic, pharmacodynamic (where applicable), and nonclinical toxicology or toxicokinetic similarity (where appropriate) while remaining competitive in the market. Thus, Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch, Two-Volume Set supplies practitioners, researchers, and scientists in the biopharmaceutical industry with a valuable resource for practical information at all stages of the biosimilar product process. N° de réf. du libraire

A propos du livre :

Book ratings provided by GoodReads) :
0 note moyenne
(0 avis)

Synopsis :

The field of biosimilar drugs is one of the hottest subjects in the filed of new drug development, with scores of companies offering seminar and training programs for prospective manufacturers and stakeholders. This book is a modern comprehensive overview of the entire biosimilar manufacturing and distribution process, covering concepts introduced by the FDA, litigation strategies, analytical methods, pharmokinetic studies, and the future and current status of biosimilar product approvals.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Détails bibliographiques

Titre : Biosimilar and Interchangeable Biologics: ...
Éditeur : Apple Academic Press Inc.
Date d'édition : 2016
Reliure : Hardback
Etat du livre : New

Meilleurs résultats de recherche sur AbeBooks

1.

ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Quantité : > 20
Vendeur
BWB
(Valley Stream, NY, Etats-Unis)
Evaluation vendeur
[?]

Description du livre État : New. Depending on your location, this item may ship from the US or UK. N° de réf. du libraire 97814822989180000000

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 273,86
Autre devise

Ajouter au panier

Frais de port : Gratuit
Vers Etats-Unis
Destinations, frais et délais

2.

NIAZI, SARFARAZ K.
Edité par CRC Press (2016)
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Quantité : 1
Vendeur
Herb Tandree Philosophy Books
(Stroud, GLOS, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre CRC Press, 2016. 223. État : NEW. 9781482298918 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. N° de réf. du libraire HTANDREE0975253

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 312,42
Autre devise

Ajouter au panier

Frais de port : EUR 9,23
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

3.

ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Quantité : 3
Vendeur
Majestic Books
(London, ,, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre État : New. pp. 1268. N° de réf. du libraire 372812185

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 319,34
Autre devise

Ajouter au panier

Frais de port : EUR 6,37
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

4.

Niazi, Sarfaraz K.
Edité par CRC Pr I Llc (2015)
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Couverture rigide Quantité : 1
Vendeur
Revaluation Books
(Exeter, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre CRC Pr I Llc, 2015. Hardcover. État : Brand New. 1st edition. 11.25x8.75x3.25 inches. In Stock. N° de réf. du libraire __1482298910

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 346,12
Autre devise

Ajouter au panier

Frais de port : EUR 6,92
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

5.

Sarfaraz K. Niazi
Edité par Apple Academic Press Inc., Canada (2016)
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Couverture rigide Quantité : 1
Vendeur
The Book Depository US
(London, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Apple Academic Press Inc., Canada, 2016. Hardback. État : New. 279 x 216 mm. Language: English . Brand New Book. What s the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch covers the strategic and tactical elements of biosimilars in two volumes. The first volume, Biosimilars and Interchangeable Biologics: Strategic Elements, explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets. This volume also examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. The second volume, Biosimilars and Interchangeable Biologics: Tactical Elements, explores the development and manufacturing of biosimilars and targets challenges surrounding the creation of these products. This includes manufacturing, production costs, and intellectual property barriers, particularly in regulated markets (regulatory agencies are still in the process of developing guidelines). It addresses the complexity of biological drugs, and it discusses specific structural elements vital to the functionality, immunogenicity, and safety of biosimilar products. This volume also provides an overall understanding of the hurdles, difficulties, and practicalities of developing a strong plan. It introduces a step-by-step approach for creating a strategy that helps develop and manufacture a biosimilar product while reducing overall production costs and meeting the requirements of biosimilarity based on analytical and functional, pharmacokinetic, pharmacodynamic (where applicable), and nonclinical toxicology or toxicokinetic similarity (where appropriate) while remaining competitive in the market. Thus, Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch, Two-Volume Set supplies practitioners, researchers, and scientists in the biopharmaceutical industry with a valuable resource for practical information at all stages of the biosimilar product process. N° de réf. du libraire AAS9781482298918

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 370,36
Autre devise

Ajouter au panier

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

6.

Sarfaraz K. Niazi
Edité par Apple Academic Press Inc., Canada (2016)
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Couverture rigide Quantité : 1
Vendeur
The Book Depository
(London, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Apple Academic Press Inc., Canada, 2016. Hardback. État : New. 279 x 216 mm. Language: English . Brand New Book. What s the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch covers the strategic and tactical elements of biosimilars in two volumes. The first volume, Biosimilars and Interchangeable Biologics: Strategic Elements, explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets. This volume also examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. The second volume, Biosimilars and Interchangeable Biologics: Tactical Elements, explores the development and manufacturing of biosimilars and targets challenges surrounding the creation of these products. This includes manufacturing, production costs, and intellectual property barriers, particularly in regulated markets (regulatory agencies are still in the process of developing guidelines). It addresses the complexity of biological drugs, and it discusses specific structural elements vital to the functionality, immunogenicity, and safety of biosimilar products. This volume also provides an overall understanding of the hurdles, difficulties, and practicalities of developing a strong plan. It introduces a step-by-step approach for creating a strategy that helps develop and manufacture a biosimilar product while reducing overall production costs and meeting the requirements of biosimilarity based on analytical and functional, pharmacokinetic, pharmacodynamic (where applicable), and nonclinical toxicology or toxicokinetic similarity (where appropriate) while remaining competitive in the market. Thus, Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch, Two-Volume Set supplies practitioners, researchers, and scientists in the biopharmaceutical industry with a valuable resource for practical information at all stages of the biosimilar product process. N° de réf. du libraire AAS9781482298918

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 370,39
Autre devise

Ajouter au panier

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

7.

Sarfaraz K. Niazi
Edité par CRC Press (2015)
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Couverture rigide Quantité : 1
Vendeur
Irish Booksellers
(Rumford, ME, Etats-Unis)
Evaluation vendeur
[?]

Description du livre CRC Press, 2015. Hardcover. État : New. book. N° de réf. du libraire 1482298910

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 428,64
Autre devise

Ajouter au panier

Frais de port : Gratuit
Vers Etats-Unis
Destinations, frais et délais

8.

Sarfaraz K. Niazi
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Couverture rigide Quantité : 1
Vendeur
AussieBookSeller
(SILVERWATER, NSW, Australie)
Evaluation vendeur
[?]

Description du livre 2016. Hardcover. État : New. 216mm x 279mm x. Hardcover. What's the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biolog.Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. 1268 pages. 4.558. N° de réf. du libraire 9781482298918

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 433,73
Autre devise

Ajouter au panier

Frais de port : EUR 25,81
De Australie vers Etats-Unis
Destinations, frais et délais

9.

Niazi, Sarfaraz K.
Edité par CRC Pr I Llc (2015)
ISBN 10 : 1482298910 ISBN 13 : 9781482298918
Neuf(s) Couverture rigide Quantité : 1
Vendeur
Revaluation Books
(Exeter, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre CRC Pr I Llc, 2015. Hardcover. État : Brand New. 1st edition. 11.25x8.75x3.25 inches. In Stock. N° de réf. du libraire zr1482298910

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 454,99
Autre devise

Ajouter au panier

Frais de port : EUR 6,92
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais